LINK‑A lncRNA is upregulated in metastatic non‑small cell lung cancer and is associated with poor prognosis

Liu,Junqiang; Song,Weian; Li,Jun; Li,Xuechang; Zhao,Rongrong; Gong,Taiqian

doi:10.3892/ol.2019.10613

LINK‑A lncRNA is upregulated in metastatic non‑small cell lung cancer and is associated with poor prognosis

Authors:
- Junqiang Liu
- Weian Song
- Jun Li
- Xuechang Li
- Rongrong Zhao
- Taiqian Gong
View Affiliations

Affiliations: Department of Thoracic Surgery, People's Liberation Army Navy General Hospital, Beijing 100048, P.R. China
Published online on: July 15, 2019 https://doi.org/10.3892/ol.2019.10613
Pages: 3049-3057
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long intergenic non‑coding RNA for kinase activation (LINK‑A) has been characterized as an oncogenic long non‑coding RNA (lncRNA) in triple‑negative breast cancer. However, its involvement in non‑small cell lung cancer (NSCLC) remains unknown. The aim of the present study was to investigate the involvement of LINK‑A in NSCLC. Expression of LINK‑A lncRNA in the plasma of patients with NSCLC collected on the day of admission and the day of discharge, and in the plasma of healthy controls, was detected by reverse transcription‑quantitative PCR. Diagnostic values of plasma LINK‑A for metastatic NSCLC were evaluated by receiver operating characteristic curve analysis. A LINK‑A lncRNA expression vector was constructed and transfected into human NSCLC cell lines, and the effects on cell migration and invasion, and Akt activation were detected by Transwell and Matrigel assays, and western blotting, respectively. Plasma levels of LINK‑A were found to be significantly higher in patients with different types of metastatic NSCLC than in patients with non‑metastatic NSCLC and healthy controls. Plasma levels of LINK‑A were lower in patients with metastatic NSCLC on the day of discharge than on the day of admission. Patients with high plasma LINK‑A had a higher mortality rate and lower progression‑free survival rate within 2 years of discharge. In conclusion, LINK‑A is overexpressed in metastatic NSCLC, and may promote the migration and invasion of NSCLC by activating Akt signaling.

View Figures

View References

1	Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015. View Article : Google Scholar : PubMed/NCBI
2	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
3	Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
4	Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
5	Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
6	Wang S, Yan Y, Cheng Z, Hu Y and Liu T: Sotetsuflavone suppresses invasion and metastasis in non-small-cell lung cancer A549 cells by reversing EMT via the TNF-α/NF-κB and PI3K/AKT signaling pathway. Cell Death Discov. 4:262018. View Article : Google Scholar : PubMed/NCBI
7	Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, Gao S, You Z, Zhan C, Liu F and Pang D: Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol. 8:4881–4891. 2015.PubMed/NCBI
8	Zhu Y, Zhang X, Qi L, Cai Y, Yang P, Xuan G and Jiang Y: HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget. 7:14429–14440. 2016.PubMed/NCBI
9	Cheetham SW, Gruhl F, Mattick JS and Dinger ME: Long noncoding RNAs and the genetics of cancer. Br J Cancer. 108:2419–2425. 2013. View Article : Google Scholar : PubMed/NCBI
10	Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, et al: The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol. 18:213–224. 2016. View Article : Google Scholar : PubMed/NCBI
11	Lin A, Hu Q, Li C, Xing Z, Ma G, Wang C, Li J, Ye Y, Yao J, Liang K, et al: The LINK-A lncRNA interacts with ptdIns (3, 4, 5) P 3 to hyperactivate AKT and confer resistance to AKT inhibitors. Nat Cell Biol. 19:238–251. 2017. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Qiao M, Sheng S and Pardee AB: Metastasis and AKT activation. Cell Cycle. 7:2991–2996. 2008. View Article : Google Scholar : PubMed/NCBI
14	Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K and Jung K: Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci. 99:1188–1194. 2008. View Article : Google Scholar : PubMed/NCBI
15	Zhou D, Xie M, He B, Gao Y, Yu Q, He B and Chen Q: Microarray data re-annotation reveals specific lncRNAs and their potential functions in non-small cell lung cancer subtypes. Mol Med Rep. 16:5129–5136. 2017. View Article : Google Scholar : PubMed/NCBI
16	Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, Yang JS, Xu TP, Liu YW, Zou YF, et al: EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. Cell Death Dis. 5:e12982014. View Article : Google Scholar : PubMed/NCBI
17	Zhao Z, Wang J, Wang S, Chang H, Zhang T and Qu J: LncRNA CCAT2 promotes tumorigenesis by over-expressed Pokemon in non-small cell lung cancer. Biomed Pharmacother. 87:692–697. 2017. View Article : Google Scholar : PubMed/NCBI
18	Shi X, Chen Y, Chen J, Feng F, Li J and He J: Antisense long noncoding RNA LOC285194 is downregulated in NSCLC and associated with poor prognosis. Chest. 149:A2562016. View Article : Google Scholar
19	Matsuoka Y, Nishi D, Tanima Y, Itakura M, Kojima M, Hamazaki K, Noguchi H and Hamazaki T: Serum pro-BDNF/BDNF as a treatment biomarker for response to docosahexaenoic acid in traumatized people vulnerable to developing psychological distress: A randomized controlled trial. Transl Psychiatry. 5:e5962015. View Article : Google Scholar : PubMed/NCBI